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Project Summary:  
 
A thermoreversible gel for antimicrobial agent delivery would provide a novel platform suitable 
for medical applications from persistent infections arising from localized biofilms. 
Thermoreversible gels could be used to coat medical implants, to inject for subdermal 
treatments, or to implement in topical applications. FDA approved Pluronics® form 
thermoreversible gels and certain Pluronics® display inherent varying degrees of antimicrobial 
activity. Pluronics® have been shown to affect efflux pumps, and reduce ATP levels within the 
bacterial cell. In combination with antibiotics and other pharmaceuticals, Pluronics® have been 
used to sequester drugs and act as a delivery vehicle. With advances in nanomedicine, 
nanoparticles offer alternatives to traditional antibiotics. Silver nanoparticles (Ag NPs) have been 
shown to inhibit enzymes, bind to DNA, and induce structural changes in bacterial membranes. 
These properties make Ag NPs a good candidate for overcoming antibiotic resistant bacteria. We 
designed a thermoreversible gel combining Pluronic® F-127 and Ag NPs that can be applied as a 
liquid to conform to the site, followed by gelation and sustained release of antimicrobials or 
other therapeutics. 
 
Aims: 
• Select thermoreversible polymer based on cost, application, and ease of implementation.  
• Synthesize Ag NPs of a consistent shape and dimension. 
• Build on the work of Wang (2007) by synthesizing Ag NPs using a thermoreversible 
solution ready for immediate use. 
• Create thermoreversible, pharmaceutical formulation containing combinations of 
Pluronic® F-127 and Ag NPs. 
• Analyze the antibiotic effects of combining Pluronic® F-127 and Ag NPs in a single 
formulation.  
• Characterize physical properties of the thermoreversible gel and Ag NPs. 
 
Background: 
 
 A worldwide increase of nosocomial infections affects thousands of people each year. 
Individuals admitted to or treated in hospitals often have a weakened immune response that 
predisposes them to infection. Not only is an acquired infection an undesirable consequence of 
being treated in a hospital, but the problem is complicated by an increasing number of infections 
from bacteria exhibiting antibiotic resistance, the result of selective pressures in the hospital 
environment. Addressing this development has proven to be a challenge to public health officials 
and hospital administrators. 
 
 The introduction of antibiotics and development of new formulations of antibiotics has 
been a focus in medicine since the early 1900s. Antibiotics have three principle targets. The first 
is the machinery involved in cell wall biosynthesis. This is accomplished using Beta-Lactam 
drugs like penicillins and cephalosporins and also the non-beta-lactam drug, vancomycin. The 
second antibiotic target includes factors involved in bacterial protein synthesis. These antibiotics 
take advantage of non-eukaryotic characteristics of ribosomal subunits and other factors involved 
with initiation, elongation, and termination in bacterial protein synthesis. Drugs effective in this 
class include macrolides, tetracyclines, and aminoglycosides. The third principle target of 
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antibiotics is bacterial DNA replication and repair. Antibiotics in this class inhibit enzymes such 
as topoisomerases and DNA gyrase and include the fluoroquinolones. A final general 
classification of antibiotics describes a drug's effectiveness as broad spectrum--affecting both 
gram positive and gram negative bacteria--and narrow spectrum, affecting only one or the other.  
Effective antibiotics target characteristics associated with bacteria but not employed by the host 
organism (Walsh 2000). 
  
 Antibiotic resistance is the result of bacterial characteristics that nullify the action of the 
drug on the target. One type of antibiotic resistance involves preventing the antibiotic from 
reaching its target in sufficient concentration. The cell accomplishes this in part by having a 
protective coating like a peptidoglycan layer and or a lipid polysaccharide layer.  Gram negative 
bacteria possess both an inner and outer plasma membrane that reduces drug diffusion rates. 
Additionally, planktonic bacteria (free floating) are more susceptible to drug transport than 
bacteria that colonize and form biofilms. The complex matrix associated with biofilms that 
normally contains an exopolysaccharide layer, significantly reduces drug diffusion and the 
ability of the drug to reach its target. An additional challenge with biofilms is that a certain 
number of bacteria are dormant and not susceptible to antibiotics that target metabolically active 
bacteria.  
 
 Another type of resistance results when both gram negative and gram positive bacteria 
produce membrane proteins that act as efflux pumps, exporting toxic materials outside of the 
cell. Efflux pumps can exhibit a low degree of specificity allowing the expulsion of multiple 
antibiotics, and in some resistance mechanisms these pumps are overproduced. The effectiveness 
of the efflux pumps is increased by the ability of the bacteria to slow diffusion rates of drugs as 
discussed above (Nikaido 1998).  Two common and problematic, opportunistic pathogens have 
developed resistance that incorporates this paradigm. Pseudomonas aeruginosa has a low 
susceptibility to antibiotic treatment due to the action of multidrug efflux pumps and low 
permeability of the antibiotics across bacterial cellular envelopes (Poole 2004).  
 
 Another means of antibiotic resistance involves the modification of the antibiotic. This is 
a prevalent method of resistance in beta-lactam antibiotics. The beta-lactam structure functions 
by transferring an acyl group to the active site of bacterial enzymes involved in the synthesis of 
cell wall components (Walsh 2000).  Resistant bacteria enzymatically hydrolyze the beta-lactam 
structure rendering the drug ineffective. Methicillin resistant Staphylococcus aureus (MRSA) is 
characterized by the ability to modify this class of antibiotics. MRSA is one of the major 
antibiotic resistant bacteria affecting hospitals and care centers and was reported to be the cause 
of 63 % of the total staph infections in the US in 2004 (Pray 2008).  
 
 Current methods employed to counter antibiotic resistance focus on: modifying the active 
portion or substituents of the active portion of antibiotics, developing new synthetic antibiotics, 
identifying the genetic causes of antibiotic resistance and suppressing the expression of those 
genes, and educating health providers and their patients about correct therapeutic doses and 
rotation of antibiotic treatment in a hospital setting (Walsh 2000).   
  
 The present project focused on the development of an engineered antimicrobial 
formulation capable of targeting multiple cell functions and countering understood antibiotic 
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resistance mechanisms.  While most antibiotics target one mode of cellular action, a new field is 
looking at general antimicrobial agents, such as silver, that target multiple cellular pathways.  
Silver has long been known as an antimicrobial agent; although the mechanism of action is not 
well understood. It is thought that silver ions interact with bacterial enzymes and deactivate 
them, bind to DNA, or induce structural changes in the cell membrane (Morones 2005 and Lok 
2007). Because silver ions target a broad range of processes, bacterial organisms are less likely 
to develop resistance to silver. Silver ions are useful in the treatment of topical bacterial 
infections in humans because silver is nontoxic to humans in minute concentrations (Pal 2007).  
 
 Even though silver ions are effective antimicrobial agents the properties of nanoparticles 
provide an interesting alternative. The field of nanotechnology is increasingly gaining more 
interest and attention.  In 2005 the total global investment in nanotechnology was $10 billion and 
is estimated to reach $1 trillion by 2015 (Roco 2005).  Ag NPs are being used in various areas 
such as textiles, pharmaceutics, paint and cosmetics due to their antimicrobial properties 
(Navarro 2008).  A true nanoparticle must have at least one dimension measuring smaller than 
100 nm (Navarro 2008). The unique properties of nanoparticles are due to their small size 
creating a high surface area to volume ratio. High specific surface area means more atoms are on 
the exterior of nanoparticles (Navarro 2008).  Indeed, the antimicrobial effects of silver increases 
as particle size decreases (Pal 2007). Ag NPs are made by two methods, using laser ablation or 
the reduction of AgNO3 by a variety of compounds (Mafune 2000 and Dadosh 2009).  Each 
method causes Ag NPs to come in a variety of shapes such as spherical, cuboidal, rod-shaped, 
and triangular.  Ayyad (2010) formed Ag NP’s in the presence of agar biopolymers and found 
that using a biopolymer matrix gives greater control over size, dispersion and shape of the 
particles. The shape and size of Ag NPs is determined using TEM imaging among other 
diagnostic methods.  Dadosh (2009) found that reduction of AgNO3 with tannic acid produced 
spherical nanoparticles with a diameter between 18-30 nm.  Wang (2004) used the Pluronic® F-
127 to create rod-shaped nanoparticles.  It has also been shown that fungi can reduce silver 
nitrate to create spherical nanoparticles with a diameter between 60-80 nm (Birla 2008). It has 
been found that the shape of the Ag NPs will determine the extent of toxicity.  Truncated 
triangular Ag NPs display the strongest antimicrobial properties followed by spherical and rod-
shaped (Pal 2007).  This could be due to the fact that the points of the triangles are able to 
puncture cells or they are more readily release silver ions. Triangular shape can be achieved by 
synthesizing Ag NP’s in the presence of UV or light radiation, aromatic solvents, or heat. 
(Deivaraj 2005, Callegari 2003, Jia 2006) 
 
 Research has been done determining the minimal inhibitory concentration (MIC) of Ag 
NPs for a variety of organisms. The MIC for E. coli is around 20 mg/L with 12 nm spherical 
nanoparticles (Sondi 2004) whereas the MIC for P. aeruginosa is 25 mg/L with 21 nm 
icosahedral nanoparticles (Morones 2005).  Using only Ag NPs as an antimicrobial agent would 
require a fairly large amount of the expensive Ag metal.  Combining Ag NPs with other 
compounds could limit the amount of silver actually needed and make medical treatments more 
economically feasible. Simple zone of inhibition tests have been done combining Ag NPs and 
antibiotics. In these tests Ag NPs did increase the zone of inhibition for ampicillin, gentamycin, 
kanamycin, streptomycin, and vancomycin against P. aeruginosa, E. coli, and S. aureus (Birla 
2008). Ag NPs have also been sequestered in hydrogel networks for controlled release and 
coated with amphiphilic molecules such as amidated polyethyleneimine (PEI) which do not 
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release the nanoparticles but still maintain the antibacterial effect (Aymonier 2002, Ma 2007, 
Chudasama 2010).  Amphiphilic molecules have also been used as a capping agent to stabilize 
Ag NPs and prevent aggregation (Shervani 2008).  
 
Thermoreversible gels are a valuable tool in drug delivery.  These gels have low critical 
solution temperatures (LCST) that allow them to have a phase transition from liquid to gel at 
temperatures ranging from 0-50 ˚C.  The liquid phase allows for easy loading of a drug and the 
gel phase provides a stable delivery vehicle.  Many thermoreversible gels are triblock 
copolymers.  Triblock copolymers are amphiphilic molecules that spontaneously form micelles 
with a hydrophobic core in aqueous environments.  This core allows sequestration of 
hydrophobic drugs in an aqueous environment (Shah 2003). This is known as the critical micelle 
concentration (CMC).  The properties of PEG-PLGA-PEG, PCL-PEG-PCL, and PEO-PPO-PEO 
(Pluronic®) triblock copolymers will be introduced and compared to determine the best delivery 
vehicle for topical antimicrobial applications. 
 
The triblock copolymer poly-(ethylene glycol-b-(DL-lactic acid-co-glycolic acid)-b-
ethylene glycol) (PEG-PLGA-PEG) has thermoreversible gelation properties, Figure 1.  PEG-
PLGA-PEG is not commercially available, but is synthesized by ring opening polymerization of 
DL-lactide and glycolide initiated by monomethoxy poly (ethylene glycol) creating PEG-PLGA.  
Adding hexamethylene diisocyanate to the diblock copolymer results in the formation of PEG-
PLGA-PEG.  This triblock copolymer will also spontaneously form micelles above certain 
concentrations with the hydrophilic PEG portion on the outside of the micelle in aqueous 
solutions (Jeong 1999).  This polymer (33 % w/w) is liquid at room temperature (viscosity of 10 
cp), but has a phase transition to a solid at body temperature (viscosity around 400 cp).  PEG-
PLGA-PEG will maintain a 3-D shape in the gel form even when shaken (Jeong 1999). This 
polymer can be naturally degraded by the body, but maintains the gel form for over 1 month 
subdermally in rats (Jeong 2000).  PEG-PLGA-PEG is not erodible by dilution and is beneficial 
as a long term drug delivery vehicle (Jeong, Aug 1999).  A drug can be sequestered in the 
polymer by simply adding it to an aqueous solution of the polymer.  No organic solvents or 
surgical procedures are required to sequester the drug in the gel matrix (Jeong 1999). 
 
 
Figure 1. Structure of PEG-PLGA-PEG triblock copolymer (Jeong 1999) 
 
Poly ethylene glycol (PEG) and poly (ε-caprolactone) (PCL) have been widely used in 
the biomedical field.  They are both well-known, FDA-approved, biodegradable and 
biocompatible materials (Liu 2007), Figure 2. PCL-PEG-PCL is a triblock copolymer that is not 
commercially available and must therefore be synthesized in lab.  
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Figure 2. Synthesis scheme and structure of PCL-PEG-PCL triblock copolymer (Liu 2007). 
 
PCL-PEG-PCL block copolymers are prepared using ring-opening polymerization of ε –
caprolactone initiated by low-molecular-weight PEG (Mn= 400-2000). The triblock components 
are combined with Sn(Oct)2 in a three-necked vessel under a dry nitrogen atmosphere. The 
mixture is then dissolved using toxic dichloromethane, precipitated in excess cold petroleum 
ether, and then filtrated.  A concentration of 15-30% or more of PCL-PEG-PCL is needed in 
solution in order to gel. Depending on ratio of PCL and PEG the gel transition temperature is 
between 10-30° C (Gong 2009). 
 
PCL-PEG-PCL was shown to be effective as a drug delivery vehicle in vitro and in vivo 
as described by Gong et. al.  In vitro testing was performed using the hydrophobic small-
molecule drug VB12, the hydrophilic small-molecule drug, honokiol, and the macromolecular,  
hydrophilic protein, BSA.  In vitro testing showed sustained drug release from a 30% w/w PCL-
PEG-PCL gel in PBS buffer for periods over 24 hours with the hydrophilic drug, and 14 days 
with the hydrophobic drug, and the highest release rate of the protein between 24 and 48 hours.  
Lidocaine release and effectiveness was tested in vivo in rats, showing effective drug release and 
effect 4 times as long as lidocaine alone.  This gel was also found to be stable in vitro in PBS 
with shaking for more than 9 weeks at 37 C. Another amphiphilic molecule is the commercially 
available surfactant known as Pluronic® (Loyd 1994). In general, poloxamers (Pluronics®) are 
composed of white, waxy, free-flowing granules that are practically odorless and tasteless (Loyd 
1994).  Pluronics® are tri-block copolymers consisting of a hydrophobic Polyoxypropylene 
(PPO) portion and a hydrophilic Polyoxyethylene (PEO) portion arranged in a PEO-PPO-PEO 
fashion with varying weight proportions of PEO/PPO (Housley 2009).  
  
Pluronics® have been used to sequester several drugs including antibiotics, anti-
inflammatory drugs, and cancer treatments. In addition to being a delivery vehicle, Pluronics® 
have inherent antimicrobial activity (Marsh 2002).  Researchers have reported that Pluronics® 
increase the cytotoxicity of anthracyclines in multiple drug resistant (MDR) cancer cells, inhibit 
drug efflux transporters in MDR cells, affect the ability of MDR cells to sequester drugs in 
cytoplasmic vesicles, and induce a reduction in ATP levels selectively in MDR cells (Kabanova 
2003). Additionally, several antibiotics coupled with various Pluronics® formulations showed 
synergistic effects on various microbes. Furthermore, the presence of Pluronics® enables a 
sustained release of the drug, rendering them effective for extended periods of time. (Veyries 
1999, Jagannath 1999) Additionally, reports indicate that exposure of mammalian cells to 
Pluronics® has negligible effects on the cells and some Pluronics® have been approved for use in 
humans by the FDA (Kabanova 2003, Faulkner 1997).  Pluronics® have a two year shelf life in 
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their original un-opened containers (BASF). 
 
 The fact that Pluronics® exist in varying sizes and PEO/PPO proportions confers unique 
properties and determines the class and name of each Pluronic®.  From our literature review 
involving numerous Pluronics® in existence, Pluronic® F-127 and F-68 have been studied and 
used in medical applications. Pluronic® F-68 has been previously subjected to numerous 
experimental and clinical studies using mice (Faulkner 1997).  This surfactant is not 
biodegradable and is rapidly excreted from the body after intravenous administration (Faulkner 
1997). Pluronic® F-68 and F-127 are commercially available as a solid flake, are soluble in 
water, and are both approved by the FDA (BASF).  We have chosen to use F-127 in our 
experiment due to the abundance of literature on this Pluronic® as well as procedures and 
methods on how to synthesize Ag NPs using Pluronic® F-127. Also, in order to form a gel using 
F-68 the concentration in solution must be at least 60% (w/w) whereas F-127 only requires 20% 
(w/w) thus making it more economical (Schmolka 1972). A greater molecular weight and higher 
percentage of PEO in a Pluronic® decreases their cytotoxicity in the body. F-68 and F-127 each 
have the same percentage of PEO, however, F-68 has a molecular weight of approximately 8,400 
Daltons and F-127 is about 12,600 Daltons (Schmolka 1972).   
 
 Pluronic® F-127 (Poloxamer 407) (Figure 3) is a nonionic surfactant that has a good 
solubilizing capacity, low toxicity, and is, therefore, considered a good medium for drug delivery 
systems. F-127 polymers are produced by condensation of ethylene oxide and propylene oxide 
(Lundsted 1972.). F-127 is more soluble in cold water than hot as a result of increased solvation 
and hydrogen bonding at lower temperatures (Gilbert 1986). F-127 in concentrations of 20 to 
30% w/w in aqueous solution shows the characteristics of reverse thermal gelation (Miyazaki 
1984). These poloxamers are liquid at refrigerated temperatures (4-5˚ C), but gel upon warming 
to room temperature (20˚C). This gelation is reversible upon cooling (Jorgensen 1997).  The 
unique thermoreversible and drug release characteristics of F-127 render it an attractive 
candidate for pharmaceutical drug delivery through different routes of administration.  Barichello 
(1999) found that F-127 gels made at a concentration of 20% released insulin better than 30% F-
127 gels.  It was also found that gels made at pH 7.0 had a better release rate of insulin than gels 
at pH 5.5 and 4.0 (Barichello 1999). 
 
 
 
 
 
 
 
Figure 3. Chemical structure of F-127 (Guzman 1994); a = 0.35, b = 0.3 
One study used Pluronic® CRL-1072 with antimicrobial agents to modulate surface 
proteins of Mycobacterium avium and increased antibiotic uptake (Jagannath 1999). 
Conveniently, Pluronics® are also commonly used as a reducing and capping agent in the 
synthesis of Ag NPs and are able to stabilize the resulting silver colloid due to their amphiphilic 
properties (Chudasama 2010, Shervani 2008, Abdullin 2009). After stabilizing Ag NPs with F-
68, Ma (2009) introduced the Pluronics® into a hydrogel as a guest molecule. They showed that 
the silver impregnated hybrid gel demonstrated good catalytic activity in the reduction of 
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methylene blue, indicating that Ag NP coated with Pluronics® retain their potency. The 
dissolution of F-127 in human body conditions has also been studied.  Liu (2006) found that the 
gel dissolution rate of 20% F-127 in simulated arterial flow conditions was 0.14 ± 0.007 g/cm2/h.   
 
In both PEG-PLGA-PEG and PCL-PEG-PCL the integrity of the gel can be maintained 
for weeks after a subdermal injection, whereas Pluronics® only last for a few hours (Gong, 
2008).  Degradation of Pluronics® occurs by surface degradation while PEG-PLGA-PEG 
degrades by chemical means (Jeong Sept 1999). PEG-PLGA-PEG can maintain a rigid 3D 
shape, but this feature would be undesirable in topical applications.  The LCST of PEG-PLGA-
PEG is very close to body temperature (37˚ C) so the triblock copolymer would not be in the gel 
state on the surface of the skin.  Pluronics®, on the other hand, are in a gel state at room 
temperatures (~20˚ C).  Both PEG-PLGA-PEG and PCL-PEG-PCL are not commercially 
available.  They would need to be synthesized by various processes.  After the synthesis is 
complete the structure would need to be verified by extensive methods such as NMR which are 
costly and time consuming.  Pluronics® are commercially available and small samples (~250 g) 
can be requested for research purposes.   
 
An understanding of properties that confer antibiotic characteristics and an understanding 
of current resistance mechanisms increases our ability to formulate and design increasingly 
effective antibiotics. For example, the antibiotic resistance effect of multi drug efflux pumps may 
be limited by creating a more hydrophilic drug, by limiting the energy available for efflux pump 
activity, or by increasing the efficiency of delivery of the antibiotics across the membrane. 
Pluronics® exhibit the potential to meet all of these requirements. The ability of bacteria to 
enzymatically modify the active portion of drugs may be decreased by the development or 
identification of materials possessing antibiotic properties. The introduction of effective new 
antimicrobial formulations is beneficial simply by the fact that it provides new treatment options 
and increases the ability of physicians to rotate treatments. As shown, Ag NPs overcome several 
resistance mechanisms simultaneously and their combination with a Pluronic® delivery vehicle 
may provide a valuable treatment alternative. 
 
Significance and innovation: 
 
 The project aims to establish a novel method for synthesizing silver nanoparticles with 
Pluronics® F-127 and simultaneously sequester them in a Pluronics® thermoreversible gel. Ag 
NPs are less likely to be overcome by antibiotic resistance. The thermoreversible properties of F-
127 allow the Ag NPs to be sequestered in a liquid phase and gel at a defined temperature.  
 
Approach: 
Methods 
1) Culturing P. aeruginosa 
a. Reviving Freeze Dried Cultures- 
i. Decrimp culture tube or break serum vial 
ii. Resuspend the cell pellet in 0.5 mL of sterile water or liquid LB media 
iii. Spread 100 µL of culture on a LB plate using aseptic technique.  Using 
the same spreader, spread an additional plate 
iv. Incubate plates at 37˚ C sealed with parafilm resting upright 
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v. Select colony and inoculate a liquid culture 
vi. Create glycerol freezer stock (750 µL of culture, 750 µL of 30 % 
glycerol).  Store at -80˚ C 
b. Antimicrobial Susceptibility Testing 
i. Take 100 µL of freezer stock and suspend in 1 mL of LB 
ii. Spread 100 µL of suspension on LB agar plate 
iii. Drop cold gel solution (8 µL) from a pipette directly onto plate as well 
as the bottom and top of a 0.6 cm diameter Whatman qualitative fast 
filter paper without disturbing the plate 
iv. Incubate plate for 24 hours at 37˚ C 
v. Measure the zone of inhibition (diameter) 
 
2) Thermoreversible Gel 
a. Make thermoreversible gel using F-127 
i. For 20% solution: Weigh 20 g F-127, add slowly to 80 ml of water at 5-
10˚ C in 250 ml beaker while stirring with a magnetic stirring bar. Leave 
container in refrigerator (4˚ C) overnight or place in ice bath and mix 
slowly until F-127 has completely dissolved (usually 4 hours). Once F-
127 has dissolved, bring it back to room temperature. (Schmolka 1972) 
ii. For 30% solution: Weigh 30 g F-127, add slowly to 70 ml of water at 5-
10˚ C in 250 ml beaker while stirring with a magnetic stirring bar. Leave 
container in refrigerator (4˚ C) overnight or place in ice bath and mix 
slowly until F-127 has completely dissolved (usually 4 hours). Once F-
127 has dissolved, bring it back to room temperature. (Schmolka 1972) 
b. Characterize antimicrobial and physical properties 
i.  Test gel on Instron to determine elasticity and ultimate tensile strength 
1. An aliquot of 5.0 g of F-127 gel was added to plastic 50 mm 
diameter Petri dishes and equilibrated to room temperature (20˚ C). 
The gels were approximately 3 mm tall when solidified in the Petri 
plates. The elastic modulus of the gels was measured using an 
Instron 5542 instrument and Bluehill software version 2.21. A 
plastic 25.5 mm diameter lexan cylindrical head was used in the 
compression test. Data was recorded from the point the head 
touched the surface of the gel. The cylinder compressed the gel at a 
rate of 1.0 mm/min and until a final depth of 1.5 mm. 
ii. Gelation Temperature/LCST 
1. To test the LCST, 5 mL samples of the gels were added to a 15 mL 
tube. Gels transitioned to the solid phase upon warming. Tubes 
were inverted using a clamp stand in a cold room (4˚ C) and 
allowed to equilibrate to the new temperature. When gels reached 
LCST they liquefied falling from the tube. Temperature was 
measured using an IR temperature gun RYOBI TV4V and 
recorded. 
3) Ag NPs 
a. There are several possible protocols for synthesis of Ag NPs.  Protocols listed are 
in order of intended use. 
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i. Using F-127: A 0.05 M AgNO3 aqueous solution, instead of water, was 
used to form a 50% F-127 gel by adding 1 gram of Pluronic® to each ml 
of AgNO3.  The resulting mixture forms a thick, yellow paste. Mixing 
was facilitated by centrifugation at 3000 rpm with a radius of 10 cm 
equally 1008 g’s. Samples were allowed to sit for variable time periods. 
The mixture was brought down to 20% and 30% solutions by adding 
dH2O and further mixed in various exposures to UV light. (Wang et al 
2004) 
ii. Tannic Acid:  20 mL of 6,8 mM tri-sodium citrate with (1.8-23.5 uM) 
tannic acid was heated to 60 C and added with vigorous stirring to 80 
mL of 0.74 mM AgNO3 preheated to 60 C.  The mixture was kept at 60 
C for 3 min, or until color turned yellow, boiled for 20 min, cooled down 
to room temperature and stored in a dark bottle at 4 C. (Dadosh 2009) 
b. Characterize Ag NPs 
i. UV-Vis scan on a Thermo Labsystems Multiskan Spectrum 
Spectrophotometer with Multiskan Spectrum 1.0 software was used to 
check for the absorbance peak at 410 nm. 
ii. Image Ag NPs to determine shape and size using AFM (Digital 
Instruments Bioscope Atomic Force Microscope, Model #BS3-N2, 
Nanoscope software version F.31R1)  
 
4) Characterize thermoreversible gel with Ag NPs 
a. Alterations to gel properties  
i. Gelation temperature 
ii. Elasticity and ultimate tensile strength  
b. Antimicrobial activity of Gel + Ag NPs 
 
Materials 
 
Glassware/Labware/General 
Supplies: Diagnostic Instruments: Specific Products: 
Carboid UV-vis spectrophotometer F-127 
Glassware        Cuvettes Deionized Water 
     250 mL beakers AFM Ethanol 
     250 mL flasks      AFM Tips Glycerol 
     125 mL flasks Instron LB-Media Components 
Petri Dishes  Glass slides      Tryptone 
Pipettes      Yeast Extract 
Pipette Tips      Agar 
Plate Spreaders Silver Nitrate 
50 mL Centrifuge tubes 
Lamp-Bulbs 
     15 W germicidal 
     7-10 mW/cm2 
        λ = 254 nm Sodium Citrate 
Microcentrifuge tubes (1.5 mL)  Citric Acid 
Biohazard Bags  Pseudomonas aeruginosa ATCC #27853 
Microwave   
Fridge/Freezer (-80˚C)   
Fume Hood (Biosafety Level 2)   
Shaker/Incubator   
Lab coats   
Gloves   
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Results  
 
Spectrophotometry 
 
 
Figure 4.  UV-Visible spectrum of Ag NPs synthesized using the tannic acid protocol. 
 
 
Figure 5.  UV-Visible spectrum of Ag NPs synthesized using 30% F-127 with silver nitrate and 
varying levels of UV exposure. 
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Figure 6.  Control solutions with and without exposure to UV. 
  
Atomic Force Microscopy 
 
 
Figure 7.  30% solution of F-127 with AgNO3 exposed to UV for 1 hour. 
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Figure 8.  30% solution of F-127 with AgNO3 exposed to UV for 6 hours. 
 
 Table 1. Effect of UV exposure on Ag NP size as measured using AFM. 
 
Effect	  of	  UV	  Exposure	  on	  Ag	  NP	  Size	  
UV	  Exposure	  (Hrs)	   Diameter	  (nm)	   St.	  Dev	   n	  
0	   29.53	   12.58	   12	  
1	   17.84	   4.25	   13	  
2	   42.1	   13.46	   16	  
4	   14.22	   3.31	   17	  
6	   27.76	   22.34	   21	  
8	   17.58	   10.46	   17	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LCST 
 
Figure 9. LCST of Pluronic® and nanoparticle preparations. NS is a non sterile sample; ST has 
been autoclaved and is sterile.  
  
Instron 
 
 
Figure 10. Triplicate of Instron compressive stress strain curve of 20% non-sterile F-127. 
Average elastic modulus is: 0.233 MPa. 
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Figure 11. Triplicate Instron compressive stress strain curve of 20% sterile F-127. Average 
elastic modulus is: 1.16 MPa. 
 
Figure 12. Triplicate of Instron compressive stress strain curve of 30% NS F-127. Average 
elastic modulus is: 2.21 MPa. 
 
 
 
  
Figure 13. Several Instron compressive stress strain curve of 20% F-127 with Ag NPs. 
Color Time (Hours) 
Maximum 
Load (N) 
Elastic 
Modulus 
(MPa) 
Red 0 2.13 0.78667 
Maroon 2 1.94 1.12329 
Green 4 1.68 0.48849 
Teal 6 2.02 0.45998 
Blue 8 1.79 0.24423 
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Zone of Inhibition 
 
 
Figure 14. Zone of inhibition images using Pluronic® and Ag NPs with confluent lawns of P. 
aeruginosa. (A) 30 µg/mL Tetracycline (B) 20% NS F-127  (C) 20% ST F-127 (D) 30% F-127 
(E) 20% F-127 with 7.5 hours UV exposure Ag NPs (F) 30% F-127 with 8 hours UV exposure 
Ag NPs.  
 
Table 2. Average diameter of the zone of inhibition tests from Figure 14. 
Treatment 
Average Diameter 
(cm) 
30 µg/ml Tetracycline 0.00 
20% NS F-127 0.90 
20% ST F-127 1.00 
30% NS F-127 1.00 
20% NS F-127+ Ag NPs 1.17 
30% NS F-127 + Ag NPs 1.23 
 
 
Discussion: 
 
Literature outlining methods for creating Ag NPs using Pluronic® suggested using 75% 
(w/w) F-127 to synthesize Ag NPs (Wang 2004). Because of the difficulty of creating an even 
dispersion of F-127 and AgNO3 at such a high concentration, attempts at synthesis using a lower 
A 
F E D 
C B 
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concentration (50% w/w) of Pluronic® were made. UV-vis scans of the resulting gels were 
compared to control solutions of Ag NPs synthesized using the Tannic acid method, Figure 4, 
silver nitrate, and F-127 only. The Tannic acid method yielded a peak centered around 400-420 
nm, which agrees with results in the literature (Callegari 2003). However, no such peak was 
observed with the Pluronic® method, though a large precipitate was present in the bottom of the 
tube suggesting that some reaction was taking place. Further literature review claimed that UV 
radiation can be useful in altering the size and shape of the particles and alter the UV-vis 
absorbance readings (Deivaraj 2005). Subsequent samples were prepared and exposed to UV 
radiation (λ=254 nm, 13 mW/cm2) for variable time periods. It was observed that the 
characteristic absorbance band (400-500 nm) appeared and became more prominent with 
increasing UV exposure, Figure 5. These results were also compared to UV treated silver nitrate 
and Pluronic®, Figure 6. To attempt to establish the cause for this absorbance increase, samples 
were imaged using AFM.  
 
AFM images of the silver nanoparticles obtained by the method above showed a 
dispersion of nanoparticle sizes, Figures 7 and 8. A parameter of interest was the effect of UV 
exposure on the particle shape and size. As previously stated, the absorbance of samples around 
410 nm grew as the UV radiation increased, this suggested that there may be some evolution in 
size, shape or concentration that caused this change. However, no distinct trend in any was 
observed in the AFM images as measured by nanoparticle height over different UV exposure 
times, Table 1. It should be noted that time constraints only allowed for a limited number of 
fields to be scanned and the volumes taken for AFM imaging were very small and may not be 
representative of the remainder of the sample since it cannot be definitively said that the sample 
was well mixed due to the viscosity and thermoreversible properties. More comprehensive 
classification of particle sizes, shapes and concentrations in the sample should therefore be 
attempted before any conclusions as to the effect of UV can be made.  
 
A possible explanation for the increase in absorbance around 400 nm without a 
perceivable evolution in Ag NP size or shape may be an encapsulation of the Ag NP’s by 
Pluronic® polymer adhesion. It is feasible that UV radiation may disrupt this adhesion and reveal 
the actual absorbance signature. Another possible explanation for the increased absorbance could 
be an alteration of the Ag NP oxidation state by the UV radiation.  
 
Two 50 mL solutions of 20% F-127 were prepared. One sample was autoclaved at 120˚ C 
for 30 minutes. Beakers were sealed with aluminum foil and parafilm and placed in the 
refrigerator at 4˚ C. The pH of the sterile (ST) and non-sterile (NS) solutions of F-127 were 
measured using pH strips. The pH of the NS sample was ~5.5 while the pH of the ST sample was 
~5.8. The pH of the 30% Ag NP 8 hour solution was ~4. The pH of the 20% 7.5 hour solution 
was ~4. The pH of the 0 hour Ag NP sample was ~4. The samples with Ag NPs have a lower pH 
than the Pluronic® alone. This could be due to various factors including UV exposure time or 
presence of Ag NPs.  
 
The Kibron, Inc. µTrough S tensiometer instrument was used to test the surface tension 
of F-127. Unfortunately the wells on the instrument were so thin that the cold F-127 began to 
warm too quickly and transitioned to the gel phase before any significant data could be obtained. 
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Unless the tensiometer could be utilized in a cold room, the surface tension of F-127 will not 
used to characterize the gel. 
 
To determine the LCST, all tubes started at a temperature of 20˚ C and four replicates 
were completed for NS and ST 20% F-127 gels 30% F-127 and for each Ag NP preparation. The 
LCST was measured using an infrared temperature sensor. Results can be found in Figure 9. The 
LCST for the 20% F-127 solutions is higher compared to the 30% F-127, and the presence of 
nanoparticles affect the LCST. A two-sided statistical analysis was run with α=0.1 and we 
observed that there was a statistically significant difference between 20% F-127 and 20% F-127 
with Ag NPs. Also, there was a statistical significance between 30% F-127 and 30% F-127 with 
Ag NPs. This suggests that Ag NPs change the LCST.  
 
An interesting phenomenon was observed with the NS gels. The gels would be solid in 
the container but after the compression test turned liquid and required days to re-solidify. This 
trend was not observed in the ST gels. During the autoclave process perhaps the polymers in the 
ST gels were cross-linked and became more stable and solid.  Figure 10 shows the stress vs. 
strain curve of NS 20% F-127 gels. One sample liquefied very quickly and provided different 
results from our other samples. The average elastic modulus was 0.233 MPa. Figure 11 shows 
the stress vs. strain curve of ST 20% F-127 gels. The average elastic modulus was 1.16 MPa. 
The ST gels could withstand greater forces when compared to the NS gels as evident in the 
elastic modulus. A 50 mL 30% F-127 solution was prepared per the above protocol. Figure 12 
shows the stress vs. strain curve for the 30% solution. The average elastic modulus was 2.21 
MPa suggesting that higher concentration of Pluronics® increase the elastic modulus. These data 
were compared to gels impregnated with Ag NPs, Figure 13. A two-sided statistical analysis was 
run at the α=0.1 level and there was not a statistically significant difference between 20% F-127 
and 20% F-127 with Ag NPs. There was, however, a statistical significance between 20% F-127 
and 30% F-127. This suggests that a higher concentration of F-127 results in an increase in 
elastic modulus.  
 
A lyophilized strain of Pseudomonas aeruginosa was obtained from ATCC #27853, 
resuspended in LB media, and spread on LB media agar plates.  After one day’s growth, two 
different colony morphologies were present on the plates.  The two colony types were streaked 
for isolation on new plates and colonies were selected for PCR and sequencing.  A universal 
primer set specific for the 16S ribosomal region was used for PCR and sequencing.  The 
sequence obtained showed 97% homology to various P. aeruginosa strains contained in the 
NCBI genome database.  Freezer stock solutions of the sequence verified P. aeruginosa colony 
were created containing 15% glycerol. 
 
The antimicrobial affect of synthesized Ag NPs was measured using zone of inhibition 
tests. When treated with a 30 μg/mL concentration of tetracycline, which was shown to inhibit 
growth of other pseudomonads, no visible zone of clearing was observed. Pluronics® alone 
slightly reduced growth around the filter paper but no zones of complete clearing were observed.  
The Pluronics® appear to form a non-fouling layer limiting attachment of the microbes to the 
surface of the LB plate. Pluronics® with Ag NPs proved most effective at inhibiting growth 
(Figure 14, Table 2). Multiple zone of inhibition tests were conducted using various UV 
exposure times as well as 20% and 30% solutions of F-127. A two-sided statistical analysis was 
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run at the α=0.1 level and we observed a significant difference between 20% F-127 and 20% F-
127 with Ag NPs. We also observed statistical significance between 30% F-127 and 30% F-127 
with Ag NPs. This suggests that the F-127 with Ag NPs significantly improve the antimicrobial 
properties of the gel.  
 
Timetable: 
Date: Task: 
September 2010 Turn in Senior Design proposal 
September 2010 Test gel preparation methods 
September 2010 Determine if frozen P. aeruginosa stocks are viable 
October 15, 2010 Turn in URCO proposal 
October 2010 Make F-127 gels 
November 2010 Test gel properties 
November 2010 Make Ag NPs with known procedure 
December 2010 Determine antimicrobial properties of gel 
December 2010 Synthesize Ag NPs using F-127 gel 
December 2010 Submit abstract to national research conference 
December 7, 2010  Turn in interim report 
January 2010  Have prepared stocks of gel and Ag NPs 
January 2010  Preliminary Ag NP characterization 
February 2011 Continue characterizing Ag NPs and gel 
March 2011 Test properties of gel and Ag NPs (LCST, antimicrobial activity, etc.) 
April 2011 Analyze data, write final paper, and prepare for final presentation. 
April 15, 2011 Turn in URCO final report 
May 2011 Present final project 
May 2011 Graduation 
 
Communication of Results: 
 
We presented our findings at the IBE Regional Conference at Utah State University in 
October 2010, Research on Capitol Hill at the Utah State Capitol in January 2011, and Utah 
Conference on Undergraduate Research at Weber State University in February 2011.  
In addition we provided weekly summaries of our progress to Dr. Taylor and Dr. Britt.  
We also provided the interim written report of our progress up to December 2010.  By the end of 
April 2011 we will have presented our project to the faculty in Biological Engineering and its 
advisory board.  
 
Benefit of Project: 
 
 The introduction of antibiotics with novel, and improved modes of action is valuable to 
many fields including human and animal health care.  As far as we know, research has been done 
analyzing the effects of combining Pluronics® with antibiotics and antibiotics with Ag NPs with 
desirable antibiotic effects.  But to date, no research has analyzed the effects of combining 
Pluronics® with Ag NPs or combining Pluronics® with Ag NPs and existing antibiotics.  
Additionally, the development of a thermoreversible formulation would allow for 
implementation as a topical solution for presurgical preparation or wound/burn treatment, an 
injectable sub dermal treatment, or into the pretreatment of prosthetic devices implanted into a 
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living system.  The broad antibiotic effects of Ag NPs and Pluronics® are such that the 
development of resistance to these materials by bacteria is less likely.  These broad effects would 
also likely counter existing and problematic multidrug resistant bacteria that plague hospitals and 
care centers.  The development of such a product would prove extremely valuable at present and 
contribute to our existing body of knowledge for further advancement.   
 
Future Studies: 
 
 Future studies could be used to test the gel with Ag NP formulation using mammalian 
cells to test for toxicity. Zone of inhibition tests using antibiotic resistance strains of bacteria 
would be beneficial to see the effects of the gel formulation. Determine concentration of silver 
ions present in the Ag NP with F-127 solution using ICP-MS. It would be interesting to view the 
Pluronic® after exposure to UV using NMR could be used to see if UV exposure changes the 
physical properties of F-127.   
 
Knowledge gained regarding implementation and management of projects: 
 
 We gained an understanding about the importance of getting funding early. At the 
beginning of this project we had to wait several weeks for our funding and therefore could not 
begin any of our experiments. We also learned the importance of dividing tasks. Each of us had 
specific roles and tasks that made the work flow more easily. Along with this division of tasks it 
was important to meet weekly as a group to discuss progress and concerns. For those weeks that 
we lacked funding, it gave us the opportunity to perform a thorough literature review. This 
helped us to understand our protocols better before starting any lab work. Lastly, we observed 
that living organisms are unpredictable and results are never what you expect.  
 
Description of Personnel:  
  
Alex Hatch: During his undergraduate studies, Alex has been involved in research projects 
involving bioplastics. Alex plans to attend medical school after his undergraduate studies and for 
this project has researched nosocomial infections and modes of antibiotic resistance. Alex also 
compiled the aims of our project as well as the benefits.  Alex brings a level of expertise in 
bacterial culturing and aseptic techniques.  Alex focused his efforts in the project to the synthesis 
and characterization of Ag NPs. 
 
Alyssa Calder: Alyssa has been involved in the laboratory of Dr. Anne Anderson and Dr. David 
Britt working with P. putida and P. chloraphis. Alyssa also brings experience in bacteria 
culturing.  For this project Alyssa gathered information and graphical materials related to 
Pluronics® as well as finding methods of characterizing nanoparticles. Alyssa outlined plans to 
communicate results of our project, organized our references, and brings a level of expertise in 
Ag NPs and Pluronics®.  Alyssa focused on creating the thermoreversible gel and characterized 
its properties as described above. Alyssa was also involved with zone of inhibition testing.  
 
Aaron Winder: During his undergraduate studies Aaron has worked in the tissue engineering 
laboratory of Dr. Soonjo Kwon involving breast cancer research. For this project Aaron found 
information relating to antibiotic resistance and modes of antibiotic resistance. Provides expertise 
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in computer programs and formulated the significance and innovation of our design project.  
Aaron also worked on the synthesis and characterization of the Ag NPs for this project. 
 
Cody Gunnell: During Cody’s undergraduate studies he volunteered in the tissue engineering 
laboratory of Dr. Soonjo Kwon researching carbon nanotubes and their effects on stem cell 
differentiation. For this project, Cody gathered information specific to Pluronic® F-127 as well as 
general information about Pluronics® and micelle formation. Wrote the description of personnel 
and provides expertise in cell culture. Cody also worked on creating the thermoreversible gel and 
characterizing its properties. Cody was also involved in zone of inhibition testing as well as 
running statistical analysis of our results.  
 
We plan on utilizing the expertise of Dr. David Britt, PhD for his knowledge involving 
surfactants, biomaterials, and gels.  
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